Doctor Interviews

Endocrine

Endocrine
Philip James

72: [Spanish] La Conexión Entre el Corazón y el Hipotiroidismo. Entrevista con la Dra. Gabriela Brenta de Buenos Aires

En esta entrevista, discutimos los siguientes temas:
* Menos función cardiovascular
* Hipertensión
* La conexión entre el funcionamiento del corazón menos y el hipotiroidismo
* El riesgo cardiovascular
* Resistencia cardiovascular
* Mayor colesterol LDL e hipotiroidismo
* Hipotiroidismo subclínico y riesgo
* Niveles de TSH
* Niveles de TSH por encima de 10
* Colesterol e hipotiroidismo
* Riesgo residual y estatinas
* Mejorando la absorción de T4
* Levotiroxina y buen cumplimiento
* Osteoporosis

Read More »
Endocrine
Philip James

65: Thyroid Cancer Does Not Respond to RAI⎢Treatment Options

In this episode, topics include:
* Drug therapy for patients that fail standard therapy; including surgery and RAI
* Not all patients have same behavior for their cancer
* Some cancers are aggressive
* Not many thyroid cancer patients are affected by this; maybe a few thousand in the U.S., but not tens of thousands
* What is the treatment protocol for therapy?
* Lenvatinib or Sorafenib is the treatment for refectory thyroid cancer
* Lenvatinib tends to be more effective
* Sorafenib is tolerated by the patient better
* Other options to consider include, molecular profiling or some thyroid cancers carry mutation that is targetable, or BRAF
* BRAF inhibitors used with thyroid cancer patients
* Molecular profiling
* DNA sequencing

Read More »
Endocrine
Philip James

64: Managing Indeterminate Thyroid Nodules, with Dr. Kimberly Vanderveen from Denver Center for Endocrine Surgery

Kimberly Vanderveen, MD is a Colorado native and graduate of Bear Creek High School in Lakewood, CO. She received her bachelor’s degree with honors from Muhlenberg College in Allentown, PA. She then earned her medical degree from Northwestern University in Chicago, IL in 2001.
In this episode, the following topics are discussed:
* Two roads of tests: rule out and malignant markers
* Rule-out tests picks up innocent behavior pattern. Most common is Afirma
* Malignant markers, or rule-in tests, are useful at determining extent of surgery, and help avoid a second or third surgery. ThyroSeq, ThyraMIR, Rosetta
* Do patients get both tests? Rule out and behavior?
* Approximately 15% of FNA’s come back indeterminate. Some centers as high as 30%
* Managing indeterminate nodules when a patient chooses no surgery.
* Taking into account emotional, financial, and lifestyle goals of the patient.

Read More »
Endocrine
Philip James

63: Take a Step Back⎢Thyroid Surgery with a Clear Mind, with Dr. Bryan McIver from Moffitt Cancer Center

Bryan McIver, MD, PhD
Dr. McIver contributes to Moffitt Cancer Center almost 20 years of clinical experience in the care of patients with endocrine diseases, specializing in the evaluation of patients with thyroid nodules and thyroid cancer. He has a particular interest in the management of patients with advanced and aggressive forms of cancer and the role of genetic and molecular techniques to improve the accuracy of diagnosis.
Most nodules are benign
When to do a biopsy
How to interpret the results of biopsy
Advances in thyroid cancer
Ultrasound technology advancements
Molecular markers
Cytopathology categorizations
Molecular marker technologies
Gene expression classifier

Read More »
Endocrine
Philip James

61: Drug Resistant Thyroid Cancer, with Dr. Carmelo Nucera from Harvard Medical School

Carmelo Nucera, M.D., Ph.D., is currently an Assistant Professor at Harvard Medical School, Boston, in the Division of Cancer Biology and Angiogenesis (Department of Pathology), Beth Israel Deaconess Medical Center. Dr. Nucera received his M.D. and Ph.D. in Experimental Endocrinology and Metabolism from Italy.
In this episode, Dr. Nucera discusses a combination drug therapy using vemurafenib and palbociclib represents a novel therapeutic strategy to treat papillary thyroid carcinoma (PTC). 

Read More »
Close Menu

Subscribe to Doctor Thyroid with Philip James Newsletter

No spam. Your information is safe.
It will not be shared with any third party.
You can unsubscribe at any time.